Arrowhead Pharmaceuticals (ARWR) Interest & Investment Income (2012 - 2026)
Arrowhead Pharmaceuticals (ARWR) posted Interest & Investment Income of $16.9 million for Q1 2026, up 73.91% on a QoQ basis from $9.7 million in Q4 2025, and up 75.44% year-over-year from $9.6 million in Q1 2025.
Arrowhead Pharmaceuticals (ARWR) Interest & Investment Income (2012 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals' Interest & Investment Income history runs 9 years deep, the most recent figure standing at $16.9 million for Q1 2026.
- Quarterly Interest & Investment Income rose 75.44% year-over-year to $16.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $46.7 million (up 51.13% YoY) and the FY2025 annual result came in at $37.3 million, up 64.12% from the prior year.
- Interest & Investment Income was $16.9 million for Q1 2026 at Arrowhead Pharmaceuticals, up from $9.7 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $16.9 million in Q1 2026 and bottomed at $1.1 million in Q1 2022.
- A 5-year average of $6.2 million and a median of $6.2 million in 2024 frame the typical range for Interest & Investment Income.
- Peak annual rise in Interest & Investment Income reached 332.64% in 2023, while the deepest fall reached 4.47% in 2023.
- Arrowhead Pharmaceuticals' Interest & Investment Income stood at $2.7 million in 2022, then advanced by 4.47% to $2.8 million in 2023, then jumped by 171.31% to $7.6 million in 2024, then grew by 27.6% to $9.7 million in 2025, then surged by 73.91% to $16.9 million in 2026.
- Business Quant data shows ARWR's Interest & Investment Income at $16.9 million in Q1 2026, $9.7 million in Q4 2025, and $9.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 44.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 19.51 Mn |
| 10 | Arrowhead Pharmaceuticals | 12.14 Bn | 10.36 Bn | - | 16.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.87 Mn |
| Dec 31, 2025 | 9.70 Mn |
| Sep 30, 2025 | 9.09 Mn |
| Jun 30, 2025 | 11.02 Mn |
| Mar 31, 2025 | 9.62 Mn |
| Dec 31, 2024 | 7.60 Mn |
| Sep 30, 2024 | 7.17 Mn |
| Jun 30, 2024 | 6.50 Mn |
| Mar 31, 2024 | 6.25 Mn |
| Dec 31, 2023 | 2.80 Mn |
| Sep 30, 2023 | 3.89 Mn |
| Jun 30, 2023 | 4.17 Mn |
| Mar 31, 2023 | 4.56 Mn |
| Dec 31, 2022 | 2.68 Mn |
| Sep 30, 2022 | 1.58 Mn |
| Jun 30, 2022 | 1.24 Mn |
| Mar 31, 2022 | 1.05 Mn |
| Mar 31, 2015 | 89,954.00 |
| Dec 31, 2014 | 23,774.00 |
| Sep 30, 2014 | 754,789.00 |